Publications
Articles
- Gagnon, M.-A., & Bacon, M.-H. (2023). Time to Improve Transparency at Health Canada’s Pest Management Regulatory Agency. CMAJ, 195(46), E1583–E1584. https://doi.org/10.1503/cmaj.231089
- Grundy, Q., Quanbury, A., Hart, D., Chaudhry, S., Tavangar, F., Lexchin, J., Gagnon, M.-A., & Tadrous, M. (2023). Prevalence and Nature of Manufacturer-Sponsored Patient Support Programs for Prescription Drugs in Canada: A Cross-Sectional Study. CMAJ, 195(46), E1565–E1576. https://doi.org/10.1503/cmaj.230841
- Bensussan, H., Durand, C., & Rikap, C. (2023). 100 years of Corporate Planning. From Industrial Capitalism to Intellectual Monopoly Capitalism through the lenses of the Harvard Business Review (1922-2021). Université de Genève. https://archive-ouverte.unige.ch/unige:171107
- Gagnon, M.-A. (2023). Commentary: Reconsidering Pharmaceutical Research and Development Investments. Healthcare Policy, 18(3). https://www.longwoods.com/content/27037/healthcare-policy/commentary-reconsidering-pharmaceutical-research-and-development-investments
- Bacon, M.-H., Vandelac, L., Gagnon, M.-A., & Parent, L. (2023). Poisoning Regulation, Research, Health, and the Environment: The Glyphosate-Based Herbicides Case in Canada. Toxics, 11(2), Article 2. https://doi.org/10.3390/toxics11020121
- García Carrillo M., Testoni F., Gagnon M.-A., Rikap C., Blaustein M.. Academic dependency: the influence of the prevailing international biomedical research agenda on Argentina’s CONICET. Heliyon. 2022 Nov 1;8(11):e11481: https://t.co/je5ozgGvqH
- Testoni F.E., García Carrillo M., Gagnon M.-A., Rikap C., Blaustein M. Whose shoulders is health research standing on? Determining the key actors and contents of the prevailing biomedical research agenda. PLOS ONE. 2021 Apr 7;16(4): e0249661: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0249661
- Lexchin J., Bero L.A., Davis C., Gagnon M.-A. Achieving greater independence from commercial influence in research. BMJ. 2021 Mar 9;372:n370 : https://www.bmj.com/content/372/bmj.n370
- Gagnon M.-A. La Canada face à l’iniquité vaccinale globale : se situer du mauvais côté de l’histoire. Rev Interventions Économiques / Papers in Political Economy [Internet]. 2021 Nov 1 [cited 2022 Nov 25]; (Hors-série. Transformations). Available from: https://journals.openedition.org/interventionseconomiques/14794
-
Gagnon, M.-A. (2021). Understanding the Battle for Universal Pharmacare in Canada; Comment on “Universal Pharmacare in Canada.” International Journal of Health Policy and Management, 10(3), 168–171. https://doi.org/10.34172/ijhpm.2020.40
-
Gagnon, M.-A. (2019). Co-pay cards in Canada: Improving choice or institutionalizing bribes? CMAJ, 191(45), E1235–E1236. https://doi.org/10.1503/cmaj.191447
-
Charbonneau, M., & Gagnon, M.-A. (2018). Surviving niche busters: Main strategies employed by Canadian private insurers facing the arrival of high cost specialty drugs. Health Policy, 122(12), 1295–1301. https://doi.org/10.1016/j.healthpol.2018.08.006
- Lexchin J., Kohler J.C., Gagnon M.-A., Crombie J., Thacker P., Shnier A.. Combating corruption in the pharmaceutical arena. Indian J Med Ethics. 2018 Sep;3(3):234–9: https://ijme.in/articles/combating-corruption-in-the-pharmaceutical-arena/
Book Chapters
- Gagnon M.-A. Combatting Corruption in the Pharmaceutical Sector. In: Faintuch J, Faintuch S, editors. Integrity of Scientific Research: Fraud, Misconduct and Fake News in the Academic, Medical and Social Environment [Internet]. Cham: Springer International Publishing; 2022: p. 477–86. Available from: https://doi.org/10.1007/978-3-030-99680-2_47
- Gagnon M.-A. Ghost management as a central feature of accumulation in corporate capitalism : The case of the global pharmaceutical sector. In: Marlène Benquet, Théo Bourgeron, editors. Accumulating Capital Today. London and New York: Routledge; 2021. : https://www.taylorfrancis.com/chapters/edit/10.4324/9781003089513-15/ghost-management-central-feature-accumulation-corporate-capitalism-marc-andr%C3%A9-gagnon
Policy Briefs & Technical Reports
- Marc-André Gagnon. Mergers and Acquisitions in the Pharmaceutical Sector; Some Necessary Considerations. Submission to US Federal Trade Commission Pharmaceutical Task Force, Project No. P212900, June 25 2021. https://carleton.ca/ghostmanagement/wp-content/uploads/Submission-on-MAs-in-the-pharmaceutical-sector.pdf
- Marc-André Gagnon, Anil Varughese et Nahya Awada. Developing a National Strategy for Rare Diseases in Canada; Some Necessary Considerations. Submitted to Health Canada, March 26 2021. https://carleton.ca/ghostmanagement/wp-content/uploads/Submission-on-rare-disease.pdf
- Marc-André Gagnon et Joel Lexchin. Soumission quant à la prise en considération d’une nouvelle capacité de biofabrication pour le Canada; De la nécessité de repenser nos manières de faire. Présenté à Innovation, Sciences et Développement Économique Canada, 12 mars 2021. https://carleton.ca/ghostmanagement/wp-content/uploads/Memoir-about-Biomanufacturing-in-Canada-3.pdf
Op-Eds & Commentaries
-
Rehn, T. (2023, November 27). Nouveaux OGM, ou quand les consultations publiques deviennent une mascarade. Le Devoir. https://www.ledevoir.com/opinion/idees/802714/idees-nouveaux-ogm-ou-quand-consultations-publiques-deviennent-mascarade [not affiliated with the GM Research Group]
- Marc-André Gagnon. “Quelles mains sont aux commandes de la recherche médicale?” Le Devoir, 25 juin 2021 : https://www.ledevoir.com/opinion/idees/613608/etude-des-interets-commerciaux-lies-de-pres-a-la-recherche-medicale
- Marc-André Gagnon. “La suspension des brevets sur les vaccins; Faire partie de la solution”. Options Politiques, 27 mai 2021 : https://policyoptions.irpp.org/magazines/may-2021/la-suspension-des-brevets-sur-les-vaccins-faire-partie-de-la-solution/
- Joel Lexchin, Barbara Mintzes, Kelly Holloway, Marc-André Gagnon. “Guidelines governing Canadian doctors’ relationships with pharma companies under review”. The Conversation, November 12 2020: https://theconversation.com/guidelines-governing-canadian-doctors-relationships-with-pharma-companies-under-review-149519
- Joel Lexchin, Barbara Mintzes,Lisa Bero, MA Gagnon, Quinn Grundy(2020). “Canada’s COVID-19 Vaccine Task Force needs better transparency about potential conflicts of interest”. The Conversation. October 8 2020: https://theconversation.com/canadas-covid-19-vaccine-task-force-needs-better-transparency-about-potential-conflicts-of-interest-147323
- Marc-André Gagnon and Louise Vandelac, 2020. “Privilégier l’industrie pharmaceutique au détriment de la recherche publique?” Le Devoir. 3 septembre 2020: https://www.ledevoir.com/opinion/idees/585254/sante-privilegier-l-industrie-pharmaceutique-au-detriment-de-la-recherche-publique
News Articles
- Crowe, K. (2023, March 23). Pharma lobby paid StatCan for reports then used in industry PR push. The Breach. Retrieved March 27, 2023, from https://breachmedia.ca/pharma-lobby-paid-statistics-canada-reports-used-industry-pr-push/.
Lectures
- Gagnon, M.-A. (2023, March). Une pilule difficile à avaler. Coeur des sciences. Montreal; Quebec. Retrieved March 27, 2023, from
Documentaries/TV Broadcasts
-
Gignac, B. (Director). (2023). Prix des médicaments: Le bon dosage. In L’enquête McSween. Télé-Québec. https://video.telequebec.tv/player/45410/stream?assetType=episodes [not affiliated with the GM Research group]